Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

Also called NCT01798238

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01798238
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01798238. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
MP-513
Intervention (Drug)
Placebo
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct01798238
Content hash
d7f9617ce6dcb473147c3a0b6c57d1010981856a96e5bb14c33d2e72e05ccf4d